Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH3 | Q9ULD8 | 1/20 | 0.46 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.43 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.42 |
| ▸ | HTR2B | P41595 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | GFER | P55789 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6288896 | 0.93 | DDB1 (0.47) | KCNH3DDB1CRBNHSD17B10ALDH1A1 | |
| SCHEMBL10977584 | 0.80 | POLB (0.40) | ALDH1A1MAPK1KMT2AMAPTCYP1A2 | |
| SCHEMBL15921255 | 0.80 | DDB1 (0.50) | DDB1CRBN | |
| SCHEMBL18780345 | 0.80 | MEN1 (0.43) | KCNH3ALDH1A1TSHRMEN1KMT2A | |
| SCHEMBL15933095 | 0.79 | TDP1 (0.46) | ALDH1A1TDP1 | |
| SCHEMBL15921072 | 0.79 | HSD17B10 (0.40) | HSD17B10 | |
| SCHEMBL878297 | 0.76 | MAPT (0.42) | HSD17B10ALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL4318982 | 0.75 | KDM4E (0.43) | MEN1KMT2AGAA | |
| SCHEMBL7039605 | 0.75 | DDB1 (0.55) | KCNH3DDB1CRBNALDH1A1TSHR | |
| SCHEMBL11487199 | 0.73 | GAA (0.40) | ALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1233962-B1 | NOVEL HETEROCYCLIC COMPOUNDS AND THEIR USE AS MEDICINES | SOD CONSEILS RECH APPLIC (FR) | 2006-03-01 | — | — | EP | claimed |
| US-20040180936-A1 | Heterocyclic compounds and their use as medicaments | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIEQUES (S.C.R.A.S.) | 2004-09-16 | — | — | US | claimed |
| EP-1233962-A2 | NOVEL HETEROCYCLIC COMPOUNDS AND THEIR USE AS MEDICINES | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2002-08-28 | — | — | EP | claimed |
| WO-2001032654-A2 | NOVEL HETEROCYCLIC COMPOUNDS AND THEIR USE AS MEDICINES | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2001-05-10 | — | — | WO | claimed |
| EP-1661564-A1 | Heterocyclic compounds and their pharmaceutical use | Société de Conseils de Recherches et d'Applications Scientifiques ( S.C.R.A.S.) (FR) | 2006-05-31 | — | — | EP | disclosed |
| EP-1233962-B1 | NOVEL HETEROCYCLIC COMPOUNDS AND THEIR USE AS MEDICINES | SOD CONSEILS RECH APPLIC (FR) | 2006-03-01 | — | — | EP | disclosed |
| US-20040180936-A1 | Heterocyclic compounds and their use as medicaments | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIEQUES (S.C.R.A.S.) | 2004-09-16 | — | — | US | disclosed |
| US-6747024-B1 | INHIBITING CALPAIN AND/OR REACTIVE OXYGEN SPECIES IN WARM-BLOODED ANIMALS | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2004-06-08 | — | — | US | disclosed |
| EP-1233962-A2 | NOVEL HETEROCYCLIC COMPOUNDS AND THEIR USE AS MEDICINES | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2002-08-28 | — | — | EP | disclosed |
| WO-2001032654-A2 | NOVEL HETEROCYCLIC COMPOUNDS AND THEIR USE AS MEDICINES | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2001-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040180936-A1 | Heterocyclic compounds and their use as medicaments | CAPN1, CAPN2, CAPNS1 | KCNH3 3040/4885DDB1 3430/4885CRBN 2889/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.